{"format":{"id":"cytokine","name":"Cytokines","blurb":"A signalling protein and the engineering that tames it: PEGylation for half-life, Fc fusion, receptor bias, an antibody to aim it at the tumour.","axes":["cytokine","engineering"],"axisLabels":["Cytokine","Engineering"],"components":[{"key":"cytokine","label":"Cytokine"},{"key":"engineering","label":"Engineering"},{"key":"target","label":"Target"}]},"counts":{"approved":4,"development":1,"stopped":2,"unclear":0,"untried":14,"drugs":8,"partial":1,"unresolved":5},"coverage":{"total":13,"full":7,"partial":1,"unresolved":5,"pct":62},"rows":[{"key":"cytokine","id":"ifn-alpha","name":"Interferon alfa","href":"/technologies/cytokine-therapy/"},{"key":"cytokine","id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/"},{"key":"cytokine","id":"il-15","name":"Interleukin-15","href":"/technologies/cytokine-therapy/"},{"key":"cytokine","id":"tnf-alpha","name":"Tumour necrosis factor alfa","href":"/technologies/cytokine-therapy/"}],"cols":[{"key":"engineering","id":"pegylated","name":"PEGylated","href":"/technologies/cytokine-therapy/"},{"key":"engineering","id":"immunocytokine","name":"Immunocytokine (antibody-aimed)","href":"/technologies/immunocytokines/"},{"key":"engineering","id":"local-delivery","name":"Local delivery","href":"/technologies/cytokine-therapy/"},{"key":"engineering","id":"recombinant","name":"Recombinant wild-type","href":"/technologies/cytokine-therapy/"},{"key":"engineering","id":"superagonist","name":"Superagonist complex","href":"/technologies/cytokine-therapy/"},{"key":"engineering","id":"not-recorded","name":"Engineering not recorded"}],"cells":[{"a":{"key":"cytokine","id":"ifn-alpha","name":"Interferon alfa","href":"/technologies/cytokine-therapy/"},"b":{"key":"engineering","id":"pegylated","name":"PEGylated","href":"/technologies/cytokine-therapy/"},"state":"approved","drugs":[{"id":"peginterferon-alfa-2b","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","state":"approved","status":"established"},{"id":"ropeginterferon-alfa-2b","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"target":[{"key":"target","id":"ifnar1","name":"Interferon alpha receptor (IFNAR1)","href":"/targets/ifnar1/"},{"key":"target","id":"jak2","name":"JAK2","href":"/targets/jak2/"}]},"evidence":[{"record":"peginterferon-alfa-2b","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/peginterferon-alfa-2b/"},{"record":"peginterferon-alfa-2b","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Adjuvant treatment of melanoma with nodal involvement after complete resection (Sylatron)","href":"/drugs/peginterferon-alfa-2b/"},{"record":"nct00539591","field":"status","kind":"trial","state":"development","label":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma: phase 2, active","href":"/trials/nct00539591/"},{"record":"registry:peginterferon-alfa-2b","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/peginterferon-alfa-2b/#registry"},{"record":"ropeginterferon-alfa-2b","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ropeginterferon-alfa-2b/"},{"record":"ropeginterferon-alfa-2b","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2019: Polycythaemia vera without symptomatic splenomegaly","href":"/drugs/ropeginterferon-alfa-2b/"},{"record":"ropeginterferon-alfa-2b","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: Polycythaemia vera","href":"/drugs/ropeginterferon-alfa-2b/"},{"record":"ropeginterferon-alfa-2b","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"ropeginterferon-alfa-2b","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/besremi"},{"record":"ropeginterferon-alfa-2b","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Besremi"},{"record":"ropeginterferon-alfa-2b","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2023","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct05482971","field":"status","kind":"trial","state":"development","label":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET: phase 2, active","href":"/trials/nct05482971/"},{"record":"nct05485948","field":"status","kind":"trial","state":"development","label":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU: phase 2, active","href":"/trials/nct05485948/"},{"record":"nct05481151","field":"status","kind":"trial","state":"development","label":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV: phase 3, active","href":"/trials/nct05481151/"},{"record":"nct04655092","field":"status","kind":"trial","state":"development","label":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients: phase 3, recruiting","href":"/trials/nct04655092/"},{"record":"nct06468033","field":"status","kind":"trial","state":"development","label":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk: phase 3, active","href":"/trials/nct06468033/"},{"record":"nct04285086","field":"status","kind":"trial","state":"development","label":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance: phase 3, active","href":"/trials/nct04285086/"},{"record":"registry:ropeginterferon-alfa-2b","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/ropeginterferon-alfa-2b/#registry"}],"reasons":[]},{"a":{"key":"cytokine","id":"ifn-alpha","name":"Interferon alfa","href":"/technologies/cytokine-therapy/"},"b":{"key":"engineering","id":"recombinant","name":"Recombinant wild-type","href":"/technologies/cytokine-therapy/"},"state":"stopped","drugs":[{"id":"interferon-alfa","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","state":"stopped","status":"historic"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{"target":[{"key":"target","id":"ifnar1","name":"Interferon alpha receptor (IFNAR1)","href":"/targets/ifnar1/"}]},"evidence":[{"record":"interferon-alfa","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/interferon-alfa/","quote":"Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents."},{"record":"interferon-alfa","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1986: Hairy cell leukaemia","href":"/drugs/interferon-alfa/"},{"record":"interferon-alfa","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1988: AIDS-related Kaposi sarcoma","href":"/drugs/interferon-alfa/"},{"record":"interferon-alfa","field":"approvals[2]","kind":"approval","state":"approved","label":"US 1995: Adjuvant high-risk melanoma (high-dose)","href":"/drugs/interferon-alfa/"},{"record":"euramos-1","field":"result","kind":"trial","state":"stopped","label":"EURAMOS-1: phase 3, negative","href":"/trials/euramos-1/","quote":"Poor responders: EFS HR 0.98 for MAPIE vs MAP, more toxicity. Good responders: no EFS benefit from interferon."},{"record":"registry:interferon-alfa","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/interferon-alfa/#registry"}],"reasons":[{"drugId":"interferon-alfa","drugName":"Interferon alfa-2a/2b","drugRoute":"/drugs/interferon-alfa/","drugState":"stopped","record":"interferon-alfa","kind":"drug","label":"Drug record status: historic","href":"/drugs/interferon-alfa/","quote":"Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents."},{"drugId":"interferon-alfa","drugName":"Interferon alfa-2a/2b","drugRoute":"/drugs/interferon-alfa/","drugState":"stopped","record":"euramos-1","kind":"trial","label":"EURAMOS-1: phase 3, negative","href":"/trials/euramos-1/","quote":"Poor responders: EFS HR 0.98 for MAPIE vs MAP, more toxicity. Good responders: no EFS benefit from interferon."}]},{"a":{"key":"cytokine","id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/"},"b":{"key":"engineering","id":"pegylated","name":"PEGylated","href":"/technologies/cytokine-therapy/"},"state":"stopped","drugs":[{"id":"bempegaldesleukin","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/","state":"stopped","status":"negative"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{"target":[{"key":"target","id":"il2rb","name":"IL2RB","href":"/targets/il2rb/"}]},"evidence":[{"record":"bempegaldesleukin","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/bempegaldesleukin/","quote":"Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials."},{"record":"registry:bempegaldesleukin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/bempegaldesleukin/#registry"}],"reasons":[{"drugId":"bempegaldesleukin","drugName":"Bempegaldesleukin","drugRoute":"/drugs/bempegaldesleukin/","drugState":"stopped","record":"bempegaldesleukin","kind":"drug","label":"Drug record status: negative","href":"/drugs/bempegaldesleukin/","quote":"Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials."}]},{"a":{"key":"cytokine","id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/"},"b":{"key":"engineering","id":"immunocytokine","name":"Immunocytokine (antibody-aimed)","href":"/technologies/immunocytokines/"},"state":"development","drugs":[{"id":"daromun","name":"Daromun","route":"/drugs/daromun/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"daromun","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/daromun/"},{"record":"nct03567889","field":"status","kind":"trial","state":"development","label":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients: phase 3, recruiting","href":"/trials/nct03567889/"},{"record":"registry:daromun","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/daromun/#registry"}],"reasons":[]},{"a":{"key":"cytokine","id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/"},"b":{"key":"engineering","id":"not-recorded","name":"Engineering not recorded"},"state":"approved","drugs":[{"id":"histamine-dihydrochloride","name":"Histamine dihydrochloride","route":"/drugs/histamine-dihydrochloride/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"histamine-dihydrochloride","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/histamine-dihydrochloride/"},{"record":"histamine-dihydrochloride","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2008: Maintenance with interleukin-2 for adults with AML in first remission (exceptional circumstances)","href":"/drugs/histamine-dihydrochloride/"},{"record":"histamine-dihydrochloride","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ceplene"},{"record":"registry:histamine-dihydrochloride","kind":"registry","state":"development","label":"ClinicalTrials.gov: 21 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/histamine-dihydrochloride/#registry"}],"reasons":[]},{"a":{"key":"cytokine","id":"il-15","name":"Interleukin-15","href":"/technologies/cytokine-therapy/"},"b":{"key":"engineering","id":"superagonist","name":"Superagonist complex","href":"/technologies/cytokine-therapy/"},"state":"approved","drugs":[{"id":"nogapendekin-alfa","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"nogapendekin-alfa","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nogapendekin-alfa/"},{"record":"nogapendekin-alfa","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: BCG-unresponsive NMIBC with CIS ± papillary tumours, with BCG","href":"/drugs/nogapendekin-alfa/"},{"record":"nogapendekin-alfa","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: BCG-unresponsive NMIBC with CIS, with BCG; 16 Feb 2026 (conditional)","href":"/drugs/nogapendekin-alfa/"},{"record":"nogapendekin-alfa","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"nogapendekin-alfa","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/anktiva"},{"record":"nogapendekin-alfa","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://products.mhra.gov.uk/?search=Anktiva"},{"record":"nct06710288","field":"status","kind":"trial","state":"development","label":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P: phase 2, recruiting","href":"/trials/nct06710288/"},{"record":"nct02138734","field":"status","kind":"trial","state":"development","label":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer: phase 1/2, active","href":"/trials/nct02138734/"},{"record":"nct06745908","field":"status","kind":"trial","state":"development","label":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In: phase 3, recruiting","href":"/trials/nct06745908/"},{"record":"nct04390399","field":"status","kind":"trial","state":"development","label":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer: phase 2, active","href":"/trials/nct04390399/"},{"record":"nct06061809","field":"status","kind":"trial","state":"development","label":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma: phase 2, active","href":"/trials/nct06061809/"},{"record":"nct03228667","field":"status","kind":"trial","state":"development","label":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors: phase 2, active","href":"/trials/nct03228667/"},{"record":"registry:nogapendekin-alfa","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/nogapendekin-alfa/#registry"}],"reasons":[]},{"a":{"key":"cytokine","id":"tnf-alpha","name":"Tumour necrosis factor alfa","href":"/technologies/cytokine-therapy/"},"b":{"key":"engineering","id":"local-delivery","name":"Local delivery","href":"/technologies/cytokine-therapy/"},"state":"approved","drugs":[{"id":"tasonermin","name":"Tasonermin","route":"/drugs/tasonermin/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"tasonermin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tasonermin/"},{"record":"tasonermin","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 1999: Irresectable soft-tissue sarcoma of the limbs with melphalan via isolated limb perfusion, as an adjunct to surgery or for palliation","href":"/drugs/tasonermin/"},{"record":"tasonermin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1999","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/beromun"},{"record":"registry:tasonermin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/tasonermin/#registry"}],"reasons":[]}],"components":{"cytokine":[{"key":"cytokine","id":"ifn-alpha","name":"Interferon alfa","href":"/technologies/cytokine-therapy/","count":3,"drugIds":["interferon-alfa","peginterferon-alfa-2b","ropeginterferon-alfa-2b"],"states":{"approved":2,"development":0,"stopped":1,"unclear":0}},{"key":"cytokine","id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/","count":3,"drugIds":["bempegaldesleukin","daromun","histamine-dihydrochloride"],"states":{"approved":1,"development":1,"stopped":1,"unclear":0}},{"key":"cytokine","id":"il-15","name":"Interleukin-15","href":"/technologies/cytokine-therapy/","count":1,"drugIds":["nogapendekin-alfa"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"cytokine","id":"tnf-alpha","name":"Tumour necrosis factor alfa","href":"/technologies/cytokine-therapy/","count":1,"drugIds":["tasonermin"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}],"engineering":[{"key":"engineering","id":"pegylated","name":"PEGylated","href":"/technologies/cytokine-therapy/","count":3,"drugIds":["bempegaldesleukin","peginterferon-alfa-2b","ropeginterferon-alfa-2b"],"states":{"approved":2,"development":0,"stopped":1,"unclear":0}},{"key":"engineering","id":"immunocytokine","name":"Immunocytokine (antibody-aimed)","href":"/technologies/immunocytokines/","count":1,"drugIds":["daromun"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"engineering","id":"local-delivery","name":"Local delivery","href":"/technologies/cytokine-therapy/","count":1,"drugIds":["tasonermin"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"engineering","id":"recombinant","name":"Recombinant wild-type","href":"/technologies/cytokine-therapy/","count":1,"drugIds":["interferon-alfa"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"engineering","id":"superagonist","name":"Superagonist complex","href":"/technologies/cytokine-therapy/","count":1,"drugIds":["nogapendekin-alfa"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}],"target":[{"key":"target","id":"ifnar1","name":"Interferon alpha receptor (IFNAR1)","href":"/targets/ifnar1/","count":2,"drugIds":["interferon-alfa","peginterferon-alfa-2b"],"states":{"approved":1,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"il2rb","name":"IL2RB","href":"/targets/il2rb/","count":1,"drugIds":["bempegaldesleukin"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"jak2","name":"JAK2","href":"/targets/jak2/","count":1,"drugIds":["ropeginterferon-alfa-2b"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}]},"drugs":[{"id":"bempegaldesleukin","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/","status":"negative","modality":"Engineered cytokine (PEGylated IL-2)","state":"stopped","confidence":"high","fields":["name","modality","mechanism","target record (drugs field)"],"components":{"cytokine":{"id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null},"engineering":{"id":"pegylated","name":"PEGylated","href":"/technologies/cytokine-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"target":{"id":"il2rb","name":"IL2RB","href":"/targets/il2rb/","confidence":"high","from":["target record (drugs field)"],"detail":null}},"evidence":[{"record":"bempegaldesleukin","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/bempegaldesleukin/","quote":"Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials."},{"record":"registry:bempegaldesleukin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/bempegaldesleukin/#registry"}],"reasons":[{"drugId":"bempegaldesleukin","drugName":"Bempegaldesleukin","drugRoute":"/drugs/bempegaldesleukin/","drugState":"stopped","record":"bempegaldesleukin","kind":"drug","label":"Drug record status: negative","href":"/drugs/bempegaldesleukin/","quote":"Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials."}]},{"id":"daromun","name":"Daromun","route":"/drugs/daromun/","status":"phase-3","modality":"Intralesional immunocytokine combination","state":"development","confidence":"high","fields":["name","modality","mechanism"],"components":{"cytokine":{"id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null},"engineering":{"id":"immunocytokine","name":"Immunocytokine (antibody-aimed)","href":"/technologies/immunocytokines/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"daromun","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/daromun/"},{"record":"nct03567889","field":"status","kind":"trial","state":"development","label":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients: phase 3, recruiting","href":"/trials/nct03567889/"},{"record":"registry:daromun","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/daromun/#registry"}],"reasons":[]},{"id":"histamine-dihydrochloride","name":"Histamine dihydrochloride","route":"/drugs/histamine-dihydrochloride/","status":"approved","modality":"Immunomodulator (H2 receptor agonist) given with interleukin-2","state":"approved","confidence":"high","fields":["name","modality","mechanism"],"components":{"cytokine":{"id":"il-2","name":"Interleukin-2","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null}},"evidence":[{"record":"histamine-dihydrochloride","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/histamine-dihydrochloride/"},{"record":"histamine-dihydrochloride","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2008: Maintenance with interleukin-2 for adults with AML in first remission (exceptional circumstances)","href":"/drugs/histamine-dihydrochloride/"},{"record":"histamine-dihydrochloride","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ceplene"},{"record":"registry:histamine-dihydrochloride","kind":"registry","state":"development","label":"ClinicalTrials.gov: 21 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/histamine-dihydrochloride/#registry"}],"reasons":[]},{"id":"interferon-alfa","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","status":"historic","modality":"Recombinant type I interferon (cytokine)","state":"stopped","confidence":"high","fields":["name","modality","mechanism","target record (drugs field)"],"components":{"cytokine":{"id":"ifn-alpha","name":"Interferon alfa","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null},"engineering":{"id":"recombinant","name":"Recombinant wild-type","href":"/technologies/cytokine-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"target":{"id":"ifnar1","name":"Interferon alpha receptor (IFNAR1)","href":"/targets/ifnar1/","confidence":"high","from":["target record (drugs field)"],"detail":null}},"evidence":[{"record":"interferon-alfa","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/interferon-alfa/","quote":"Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents."},{"record":"interferon-alfa","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1986: Hairy cell leukaemia","href":"/drugs/interferon-alfa/"},{"record":"interferon-alfa","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1988: AIDS-related Kaposi sarcoma","href":"/drugs/interferon-alfa/"},{"record":"interferon-alfa","field":"approvals[2]","kind":"approval","state":"approved","label":"US 1995: Adjuvant high-risk melanoma (high-dose)","href":"/drugs/interferon-alfa/"},{"record":"euramos-1","field":"result","kind":"trial","state":"stopped","label":"EURAMOS-1: phase 3, negative","href":"/trials/euramos-1/","quote":"Poor responders: EFS HR 0.98 for MAPIE vs MAP, more toxicity. Good responders: no EFS benefit from interferon."},{"record":"registry:interferon-alfa","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/interferon-alfa/#registry"}],"reasons":[{"drugId":"interferon-alfa","drugName":"Interferon alfa-2a/2b","drugRoute":"/drugs/interferon-alfa/","drugState":"stopped","record":"interferon-alfa","kind":"drug","label":"Drug record status: historic","href":"/drugs/interferon-alfa/","quote":"Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents."},{"drugId":"interferon-alfa","drugName":"Interferon alfa-2a/2b","drugRoute":"/drugs/interferon-alfa/","drugState":"stopped","record":"euramos-1","kind":"trial","label":"EURAMOS-1: phase 3, negative","href":"/trials/euramos-1/","quote":"Poor responders: EFS HR 0.98 for MAPIE vs MAP, more toxicity. Good responders: no EFS benefit from interferon."}]},{"id":"nogapendekin-alfa","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","status":"approved","modality":"IL-15 superagonist (intravesical, with BCG)","state":"approved","confidence":"high","fields":["name","modality","mechanism"],"components":{"cytokine":{"id":"il-15","name":"Interleukin-15","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null},"engineering":{"id":"superagonist","name":"Superagonist complex","href":"/technologies/cytokine-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"nogapendekin-alfa","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nogapendekin-alfa/"},{"record":"nogapendekin-alfa","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: BCG-unresponsive NMIBC with CIS ± papillary tumours, with BCG","href":"/drugs/nogapendekin-alfa/"},{"record":"nogapendekin-alfa","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: BCG-unresponsive NMIBC with CIS, with BCG; 16 Feb 2026 (conditional)","href":"/drugs/nogapendekin-alfa/"},{"record":"nogapendekin-alfa","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"nogapendekin-alfa","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/anktiva"},{"record":"nogapendekin-alfa","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://products.mhra.gov.uk/?search=Anktiva"},{"record":"nct06710288","field":"status","kind":"trial","state":"development","label":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P: phase 2, recruiting","href":"/trials/nct06710288/"},{"record":"nct02138734","field":"status","kind":"trial","state":"development","label":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer: phase 1/2, active","href":"/trials/nct02138734/"},{"record":"nct06745908","field":"status","kind":"trial","state":"development","label":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In: phase 3, recruiting","href":"/trials/nct06745908/"},{"record":"nct04390399","field":"status","kind":"trial","state":"development","label":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer: phase 2, active","href":"/trials/nct04390399/"},{"record":"nct06061809","field":"status","kind":"trial","state":"development","label":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma: phase 2, active","href":"/trials/nct06061809/"},{"record":"nct03228667","field":"status","kind":"trial","state":"development","label":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors: phase 2, active","href":"/trials/nct03228667/"},{"record":"registry:nogapendekin-alfa","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/nogapendekin-alfa/#registry"}],"reasons":[]},{"id":"peginterferon-alfa-2b","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","status":"established","modality":"Pegylated type I interferon, weekly subcutaneous injection","state":"approved","confidence":"high","fields":["name","modality","mechanism","targets"],"components":{"cytokine":{"id":"ifn-alpha","name":"Interferon alfa","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null},"engineering":{"id":"pegylated","name":"PEGylated","href":"/technologies/cytokine-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"target":{"id":"ifnar1","name":"Interferon alpha receptor (IFNAR1)","href":"/targets/ifnar1/","confidence":"high","from":["targets"],"detail":null}},"evidence":[{"record":"peginterferon-alfa-2b","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/peginterferon-alfa-2b/"},{"record":"peginterferon-alfa-2b","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Adjuvant treatment of melanoma with nodal involvement after complete resection (Sylatron)","href":"/drugs/peginterferon-alfa-2b/"},{"record":"nct00539591","field":"status","kind":"trial","state":"development","label":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma: phase 2, active","href":"/trials/nct00539591/"},{"record":"registry:peginterferon-alfa-2b","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/peginterferon-alfa-2b/#registry"}],"reasons":[]},{"id":"ropeginterferon-alfa-2b","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/","status":"approved","modality":"Long-acting mono-pegylated interferon alfa","state":"approved","confidence":"high","fields":["name","modality","mechanism","targets"],"components":{"cytokine":{"id":"ifn-alpha","name":"Interferon alfa","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null},"engineering":{"id":"pegylated","name":"PEGylated","href":"/technologies/cytokine-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"target":{"id":"jak2","name":"JAK2","href":"/targets/jak2/","confidence":"high","from":["targets"],"detail":null}},"evidence":[{"record":"ropeginterferon-alfa-2b","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ropeginterferon-alfa-2b/"},{"record":"ropeginterferon-alfa-2b","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2019: Polycythaemia vera without symptomatic splenomegaly","href":"/drugs/ropeginterferon-alfa-2b/"},{"record":"ropeginterferon-alfa-2b","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: Polycythaemia vera","href":"/drugs/ropeginterferon-alfa-2b/"},{"record":"ropeginterferon-alfa-2b","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"ropeginterferon-alfa-2b","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/besremi"},{"record":"ropeginterferon-alfa-2b","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Besremi"},{"record":"ropeginterferon-alfa-2b","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2023","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct05482971","field":"status","kind":"trial","state":"development","label":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET: phase 2, active","href":"/trials/nct05482971/"},{"record":"nct05485948","field":"status","kind":"trial","state":"development","label":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU: phase 2, active","href":"/trials/nct05485948/"},{"record":"nct05481151","field":"status","kind":"trial","state":"development","label":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV: phase 3, active","href":"/trials/nct05481151/"},{"record":"nct04655092","field":"status","kind":"trial","state":"development","label":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients: phase 3, recruiting","href":"/trials/nct04655092/"},{"record":"nct06468033","field":"status","kind":"trial","state":"development","label":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk: phase 3, active","href":"/trials/nct06468033/"},{"record":"nct04285086","field":"status","kind":"trial","state":"development","label":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance: phase 3, active","href":"/trials/nct04285086/"},{"record":"registry:ropeginterferon-alfa-2b","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/ropeginterferon-alfa-2b/#registry"}],"reasons":[]},{"id":"tasonermin","name":"Tasonermin","route":"/drugs/tasonermin/","status":"approved","modality":"Recombinant tumour necrosis factor alpha for isolated limb perfusion","state":"approved","confidence":"high","fields":["name","modality","mechanism"],"components":{"cytokine":{"id":"tnf-alpha","name":"Tumour necrosis factor alfa","href":"/technologies/cytokine-therapy/","confidence":"high","from":["name","modality","mechanism"],"detail":null},"engineering":{"id":"local-delivery","name":"Local delivery","href":"/technologies/cytokine-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tasonermin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tasonermin/"},{"record":"tasonermin","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 1999: Irresectable soft-tissue sarcoma of the limbs with melphalan via isolated limb perfusion, as an adjunct to surgery or for palliation","href":"/drugs/tasonermin/"},{"record":"tasonermin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1999","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/beromun"},{"record":"registry:tasonermin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/tasonermin/#registry"}],"reasons":[]}],"unresolved":[{"id":"elritercept","name":"Elritercept","route":"/drugs/elritercept/","format":"cytokine","modality":"Activin receptor type IIA ligand trap (fusion protein), subcutaneous","missing":["cytokine","engineering","target"],"why":"No cytokine on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"jk08","name":"JK08","route":"/drugs/jk08/","format":"cytokine","modality":"fusion protein or cytokine","missing":["cytokine","engineering"],"why":"No cytokine on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"mifamurtide","name":"Mifamurtide","route":"/drugs/mifamurtide/","format":"cytokine","modality":"Liposomal muramyl tripeptide (macrophage activator)","missing":["cytokine","engineering","target"],"why":"No cytokine on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"oprelvekin","name":"Oprelvekin","route":"/drugs/oprelvekin/","format":"cytokine","modality":"Recombinant interleukin-11, subcutaneous injection","missing":["cytokine"],"why":"No cytokine on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tagraxofusp","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","format":"cytokine","modality":"Recombinant cytotoxin (IL-3 fused to diphtheria toxin)","missing":["cytokine"],"why":"No cytokine on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."}],"stopped":[{"drugId":"bempegaldesleukin","drugName":"Bempegaldesleukin","drugRoute":"/drugs/bempegaldesleukin/","drugState":"stopped","record":"bempegaldesleukin","kind":"drug","label":"Drug record status: negative","href":"/drugs/bempegaldesleukin/","quote":"Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials."},{"drugId":"interferon-alfa","drugName":"Interferon alfa-2a/2b","drugRoute":"/drugs/interferon-alfa/","drugState":"stopped","record":"interferon-alfa","kind":"drug","label":"Drug record status: historic","href":"/drugs/interferon-alfa/","quote":"Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents."},{"drugId":"interferon-alfa","drugName":"Interferon alfa-2a/2b","drugRoute":"/drugs/interferon-alfa/","drugState":"stopped","record":"euramos-1","kind":"trial","label":"EURAMOS-1: phase 3, negative","href":"/trials/euramos-1/","quote":"Poor responders: EFS HR 0.98 for MAPIE vs MAP, more toxicity. Good responders: no EFS benefit from interferon."}],"proposed":[],"note":"Every state is derived from the records named in evidence; untried means no medicine in this corpus combines the two parts. Proposed cells are hypotheses from the open pipeline (docs/OPEN-PIPELINE.md), not records of a medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}